Section Arrow
Quote
KLRS.NASDAQ
- Kalaris Therapeutics Inc
Quotes are at least 15-min delayed:2025/08/06 16:23 EDT
After Hours
Last
 2.75
-- (--)
Bid
2.36
Ask
2.75
High 2.75 
Low 2.75 
Volume 501 
Regular Hours
Last
 2.64
+0.09 (+3.53%)
Day High 
2.7655 
Prev. Close
2.55 
1-M High
2.97 
Volume 
72.10K 
Bid
2.36
Ask
2.75
Day Low
2.54 
Open
2.585 
1-M Low
2.33 
Market Cap 
47.69M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.72 
20-SMA 2.6 
50-SMA 2.69 
52-W High 24.15 
52-W Low 2.28 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.71/--
Enterprise Value
47.69M
Balance Sheet
Book Value Per Share
3.42
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
PHGEBiomX Inc0.65+0.215+49.43%0.03PE
After Hours 0.5502 -0.0998 -15.35%
NCNANuCana plc0.0404-0.0021-4.94%-- 
After Hours 0.04005 -0.00035 -0.87%
BTAIBioXcel Therapeutics Inc3.32+0.35+11.78%-- 
After Hours 3.4201 +0.1001 +3.02%
ADAPAdaptimmune Therapeutics plc0.0803-0.0148-15.56%-- 
After Hours 0.0805 +0.0002 +0.25%
GERNGeron Corp1.39+0.19+15.83%-- 
After Hours 1.36 -0.03 -2.16%
Quotes are at least 15-min delayed：2025/08/06 16:23 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.